Novartis News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

29.01.20	Novartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019 (GlobeNewswire)
20.01.20	Novartis announces EU approval of Mayzent® (siponimod) for adult patients with secondary progressive multiple sclerosis (SPMS) with active disease (GlobeNewswire)
16.01.20	Public-Private Collaboration Commits to Accelerate Access to Health Services in Africa, Reaching 1.7 Million People (GlobeNewswire)
06.01.20	Novartis successfully completes acquisition of The Medicines Company, adding a potentially first-in-class, investigational cholesterol-lowering therapy inclisiran (GlobeNewswire)
06.01.20	Novartis completes tender offer for all outstanding shares of The Medicines Company (GlobeNewswire)
16.12.19	Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma (GlobeNewswire)
13.12.19	Novartis receives positive CHMP opinion for Beovu® (brolucizumab) for the treatment of wet AMD (GlobeNewswire)
09.12.19	Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting (GlobeNewswire)
06.12.19	Novartis Phase III data on new inhaled dual combination QMF149 show significant improvement across key asthma outcomes versus monotherapy (GlobeNewswire)
05.12.19	Novartis expects to sustain long-term growth with a robust pipeline of 25+ potential blockbusters highlighted at R&D Day (GlobeNewswire)
05.12.19	Novartis tender offer for The Medicines Company commences (GlobeNewswire)
24.11.19	Novartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of death (GlobeNewswire)
17.11.19	Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF (GlobeNewswire)
15.11.19	New Novartis medicine Adakveo® (crizanlizumab) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease (GlobeNewswire)
15.11.19	Novartis receives positive CHMP opinion for Mayzent® (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS) (GlobeNewswire)
12.11.19	Sandoz presents real-world data showing effectiveness of Erelzi® (etanercept-szzs) in rheumatic disease treatment (GlobeNewswire)
12.11.19	New Novartis PREVENT data show Cosentyx® delivers early relief in axial spondyloarthritis (GlobeNewswire)
11.11.19	Sandoz announces agreement to acquire Aspen’s Japanese operations and associated assets, strengthening position in world’s third largest generics market (GlobeNewswire)
05.11.19	Sandoz receives US FDA approval for long-acting oncology supportive care biosimilar Ziextenzo™ (pegfilgrastim-bmez) (GlobeNewswire)
01.11.19	Novartis Cosentyx® shows encouraging results versus Humira®* from first-of-its-kind head-to-head trial in psoriatic arthritis (GlobeNewswire)
30.10.19	Novartis announces AVXS-101 intrathecal study update (GlobeNewswire)
24.10.19	Novartis receives approval for Cosentyx® label update in Europe to include dosing flexibility in ankylosing spondylitis (GlobeNewswire)
22.10.19	Novartis verzeichnet ein weiteres starkes Quartal mit zweistelligem Umsatz-wachstum und höherer Kerngewinnmarge1; Umsatz- und Gewinnerwartung für 2019 angehoben; US-Einführung von Beovu (GlobeNewswire)
22.10.19	Novartis delivered another strong quarter with double digit sales growth and core1 margin expansion; 2019 sales and profit guidance raised; Beovu launched in US (GlobeNewswire)
08.10.19	Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept (GlobeNewswire)
02.10.19	Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum (GlobeNewswire)
01.10.19	Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence (GlobeNewswire)
30.09.19	Novartis announces positive results from Phase III PALLADIUM study of inhaled combination QMF149 in patients with uncontrolled asthma (GlobeNewswire)
30.09.19	Novartis announces positive results from Phase III IRIDIUM study of inhaled combination QVM149 in patients with uncontrolled asthma (GlobeNewswire)
29.09.19	Novartis Kisqali® delivers consistently superior overall survival – MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients (GlobeNewswire)
19.09.19	AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma® in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (S (GlobeNewswire)
18.09.19	Positive results from Novartis five-year VERIFY study in type 2 diabetes demonstrate long-term clinical benefits of early combination treatment with Galvus® and metformin (GlobeNewswire)
17.09.19	Novartis Cosentyx® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis (GlobeNewswire)
13.09.19	Novartis Phase III ASCLEPIOS trials demonstrate robust efficacy of ofatumumab in patients with relapsing multiple sclerosis (GlobeNewswire)
03.09.19	Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine (GlobeNewswire)
02.09.19	Entresto improved measures of heart structure and function in HFrEF patients in new Novartis study; additional data complement findings (GlobeNewswire)
01.09.19	Novartis PARAGON-HF trial suggests Entresto® benefit in HFpEF patients but narrowly misses primary endpoint (GlobeNewswire)
30.08.19	Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies (GlobeNewswire)
09.08.19	Sandoz will appeal District Court of New Jersey ruling in biosimilar Erelzi® (etanercept-szzs) US patent case (GlobeNewswire)
07.08.19	Novartis stands behind Zolgensma® (onasemnogene abeparvovec-xioi) for the treatment of children less than 2 years of age with spinal muscular atrophy (GlobeNewswire)
31.07.19	Novartis Kisqali significantly prolongs life in women with HR+/HER2- advanced breast cancer now in two distinct Phase III trials (GlobeNewswire)
29.07.19	Novartis provides update on Phase III PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFpEF) (GlobeNewswire)
26.07.19	Novartis receives positive CHMP opinion for Lucentis® treatment in preterm infants with retinopathy of prematurity (ROP), a disease causing visual impairment and blindness (GlobeNewswire)
22.07.19	Sandoz announces first patient enrolled in clinical study for proposed biosimilar denosumab in osteoporosis (GlobeNewswire)
18.07.19	Novartis delivers strong sales, double digit core operating income growth and launches Zolgensma and Piqray in second quarter; sales and profit guidance increased (GlobeNewswire)
18.07.19	Novartis erzielt im zweiten Quartal starke Umsätze, eine zweistellige Steigerung des operativen Kernergebnisses und lanciert Zolgensma und Piqray; Anhebung der Umsatz- und Gewinnerwartung (GlobeNewswire)
16.07.19	FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101) (GlobeNewswire)
11.07.19	Novartis, Amgen and Banner Alzheimer's Institute discontinue clinical program with BACE inhibitor CNP520 for Alzheimer's prevention (GlobeNewswire)
01.07.19	Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio (GlobeNewswire)
14.06.19	Novartis continues to innovate in CML with long-term treatment-free remission results following Tasigna® use and promising combination data with investigational compound asciminib (ABL001) (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

18:01		Dow Jones aktuell: Dow Jones notiert am Mittag im Plus
18:01		Börse New York in Grün: So steht der NASDAQ 100 aktuell
17:58		Minuszeichen in London: FTSE 100 schwächelt zum Ende des Freitagshandels
17:58		Handel in Europa: STOXX 50 schliesst im Minus
17:58		Schwacher Handel: SMI schliesst mit Verlusten
17:58		Verluste in Europa: Euro STOXX 50 letztendlich leichter
17:58		SPI-Handel aktuell: SPI zum Handelsende leichter